Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures

Neuroscience
2004
https://pubmed.ncbi.nlm.nih.gov/15541894/

Problem drinking and low-dose naltrexone-assisted opioid detoxification

J Stud Alcohol Drugs
May 2011
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084365/

A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence

Drug Alcohol Depend
15 July 2004
https://pubmed.ncbi.nlm.nih.gov/15225891/

Aim: To investigate the efficacy of low doses of naltrexone in relapse prevention for heroin dependence.

Design: Double blind, randomised comparison of three groups-Group 1 taking 50mg per day, Group 2: 0.5mg per day, and Group 3: 0.05 mg per day.

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization

Medical Sciences
21 September 2018
https://pdfs.semanticscholar.org/c495/7df14b181c4ae963a80fdeaf38c5cbb1a9e3.pdf?_ga=2.217655315.460139797.1583212532-762170649.1583212532

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation

Expert Opin Investig Drugs
August 2007
https://www.ncbi.nlm.nih.gov/pubmed/17685875

Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study

J Opioid Manag
May-Jun 2007
https://pubmed.ncbi.nlm.nih.gov/18027539/

Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone

Encephale
Mar-Apr 1993
http://www.ncbi.nlm.nih.gov/pubmed/8275903

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

J Mult Scler
September 2008
https://www.ncbi.nlm.nih.gov/pubmed/18728058

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling

J Pain
August 2008
https://www.ncbi.nlm.nih.gov/pubmed/18468954

Oxycodone combined with opioid receptor antagonists: efficacy and safety

Expert Opin Drug Saf
May 2013
https://pubmed.ncbi.nlm.nih.gov/23534906/

Introduction: A mu receptor antagonist combined with oxycodone (OXY) may improve pain control, reduce physical tolerance and withdrawal, minimizing opioid-related bowel dysfunction and act as an abuse deterrent.